These vesicles clustered with HER2-targeting peptides on their surface exhibited high reactivity to breast cancer cells with a low expression of receptors like MDA-MB-231 or MCF7 compared to uniformly functionalised nanoparticles (nanoparticles with PEG and HER2 targeting monoclonal antibody). Here, ERBB2 is linked to breast cancer.